Jarolim Petr
Department of Pathology, Division of Clinical Laboratories, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Cardiovasc Pathol. 2006 May-Jun;15(3):144-9. doi: 10.1016/j.carpath.2006.01.001.
The incidence of heart failure has been steadily increasing over the past several decades. High readmission rates in patients with acute decompensated heart failure led to the search for biomarkers that could predict future clinical course and would, in an ideal case, enable monitoring of patients with heart failure and guidance of their therapy. From among several promising markers, the B-type natriuretic peptide and the biologically inactive N-terminal portion of its pro-hormone, NT-proBNP, have become the most frequently used analytes. Other known markers, such as atrial natriuretic peptide and endothelin-1, are currently used for research purposes. The development of additional biomarkers will be an important step from improving diagnosis and treatment of patients with chronic and acute decompensated heart failure.
在过去几十年中，心力衰竭的发病率一直在稳步上升。急性失代偿性心力衰竭患者的高再入院率促使人们寻找能够预测未来临床病程的生物标志物，在理想情况下，这些生物标志物能够监测心力衰竭患者并指导其治疗。在几种有前景的标志物中，B型利钠肽及其前体激素的无生物活性的N末端部分NT-proBNP，已成为最常用的分析物。其他已知的标志物，如心房利钠肽和内皮素-1，目前用于研究目的。开发更多的生物标志物将是改善慢性和急性失代偿性心力衰竭患者诊断和治疗的重要一步。
